Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Sagent Appoints Allan Oberman CEO | Contract Pharma

What are you searching for?

Sign in
Breaking News, Promotions & Moves

Sagent Appoints Allan Oberman CEO

Most recently headed up Teva Americas Generics

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Sagent Pharmaceuticals Inc., a provider of specialty pharmaceutical products with a specific emphasis on the injectables market, has named Allan Oberman as chief executive officer and a member of the board of directors, effective immediately upon receipt of a U.S. work visa.

“Allan is a proven leader with impeccable credentials and strategic instincts that will serve Sagent well as we enter our next phase of growth,” said Robert Flanagan, chairman of Sagent’s board of directors. “Allan has deep knowledge and extensive experience in the global generic market. His proven ability to build value while communicating a clear and consistent vision will enable him to provide strong leadership as we look to capitalize on what we believe are significant market opportunities over the coming years. The board is confident that Allan is uniquely qualified to refine our strategy and unify the company around a global plan to accelerate growth.”

Mr. Oberman most recently served as president and chief executive officer of Teva Americas Generics, a subsidiary of Teva Pharmaceutical Industries Ltd., from November 2012 until December 2014.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics